<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738827</url>
  </required_header>
  <id_info>
    <org_study_id>URU05</org_study_id>
    <nct_id>NCT02738827</nct_id>
  </id_info>
  <brief_title>Diode Laser Treatment of Bladder Tumors</brief_title>
  <official_title>Diode Laser Treatment of Pta Low Grade Bladder Tumors in the Outpatient Department.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gregers Gautier Hermann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Bispebjerg and Frederiksberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laser treatment of pTa low grade bladder tumours in the outpatient department&#xD;
&#xD;
      Number of Subjects/Centres Planned: 20 patients will be included in this study. The study&#xD;
      will be performed at Department of Urology, Bispebjerg-Frederiksberg Hospital, Copenhagen,&#xD;
      Denmark.&#xD;
&#xD;
      Primary Objective: To show that small pTa bladder tumours safely can be removed with diode&#xD;
      laser in an outpatient department Secondary Objective: To evaluate the patients experience&#xD;
      with the laser treatment using QOL questionaires (symptom evaluation) and Visual Analog Scale&#xD;
      Score (pain evaluation).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Laser treatment of pTa low grade bladder tumours in the outpatient department&#xD;
&#xD;
      Number of Subjects/Centres Planned: 20 patients will be included in this study. The study&#xD;
      will be performed at Department of Urology, Bispebjerg-Frederiksberg Hospital, Copenhagen,&#xD;
      Denmark.&#xD;
&#xD;
      Primary Objective: To show that small pTa bladder tumours safely can be removed with diode&#xD;
      laser in an outpatient department Secondary Objective: To evaluate the patients experience&#xD;
      with the laser treatment using QOL questionaires (symptom evaluation) and Visual Analog Scale&#xD;
      Score (pain evaluation).&#xD;
&#xD;
      Study Design: Open prospective study in patients with recurrent pTa low grade bladder&#xD;
      tumours.&#xD;
&#xD;
      All patients will have their bladder tumour removed using a diode laser. The treatment will&#xD;
      take place in the outpatient department (OPD) without any pain treatment. Biopsy from the&#xD;
      tumour will be obtained before the procedure. If the biopsy shows low grade non-invasive&#xD;
      bladder tumour, flexible cystoscopy will be repeated one month later in the OPD. At both&#xD;
      procedures biopsy will be taken from the laser treated area.&#xD;
&#xD;
      If the per-operative biopsy shows high grade or invasive tumour, the patient will be referred&#xD;
      for a re-resection at the operating theatre during admittance to the urology ward.&#xD;
&#xD;
      The pain is valuated by a Visual Analogue Scale Score and filled out immediately after each&#xD;
      procedure.&#xD;
&#xD;
      Treatment induced symptoms will be evaluated using a QOL questionnaire which the patient&#xD;
      fills out one week after the laser treatment and one week after the cystoscopies.&#xD;
&#xD;
      Population: Patients with histologically confirmed pTa urothelial bladder tumours Number of&#xD;
      Subjects: Twenty patients Selection of Subjects: Patients scheduled for a trans urethral&#xD;
      resection of bladder tumour (TUR-B) less than 1,5 cm at the operating theatre under general&#xD;
      anaesthesia and without concomitant therapy with anticoagulants as Marevan, Marcoumar, and&#xD;
      the new anticoagulants as Pradaxa etc. will after informed consent be included in the study.&#xD;
&#xD;
      Equipment:&#xD;
&#xD;
      Diode laser Storz, SPIES Biopsy forceps, Storz&#xD;
&#xD;
      Key Dates:&#xD;
&#xD;
      Overall duration of the study: 6 months included 1 months follow up Efficacy and Safety&#xD;
      Variables Primary Endpoint: proportion of patients where the bladder tumours are completely&#xD;
      removed by one laser treatment.&#xD;
&#xD;
      Secondary Endpoints:&#xD;
&#xD;
        -  Portion of general urinary problems and QOL after laser treatment compared to cystoscopy&#xD;
           and biopsy in the OPD&#xD;
&#xD;
        -  Pain at the laser treatment and the cystoscopy assessed by Visual Analog Scale (VAS)&#xD;
           Score.&#xD;
&#xD;
      Statistical Methods and Planned Analysis: Non-parametric and descriptive statistics will be&#xD;
      performed&#xD;
&#xD;
      Parameters in the case report form (CRF):&#xD;
&#xD;
      Bladder cancer diagnosis (pTa low grade)&#xD;
&#xD;
        -  Age&#xD;
&#xD;
        -  Sex&#xD;
&#xD;
        -  Mapping of lesions in normal, Clara Chrome, Spectra A and B filter cystoscopy&#xD;
&#xD;
        -  Histology of all suspicious lesions&#xD;
&#xD;
        -  SEPARATE CYSTOSCOPYFORM for laser TUR-B and the two follow up cystoscopies&#xD;
&#xD;
        -  The duration of the laser treatment&#xD;
&#xD;
        -  Expected clearance after the laser TUR-B&#xD;
&#xD;
        -  The visibility during the laser TUR-B&#xD;
&#xD;
        -  Visual Analog Scale Score result (to measure pain when laser treatment is performed and&#xD;
           biopsies are taken in the OPD)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">March 1, 2017</completion_date>
  <primary_completion_date type="Actual">February 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumour clearance</measure>
    <time_frame>1 month</time_frame>
    <description>No bladder tumor tissue in biopsies obtained from areas where a bladder tumor one month earlier has been removed by use of diode laser.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Laser treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention is diode laser treatment of bladder cancer through a cystoscope without sedation of the patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser treatment</intervention_name>
    <description>Intervention is diode laser treatment of bladder cancer through a cystoscope in the outpatient department</description>
    <arm_group_label>Laser treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recurrence of pTa low grade urothelial bladder tumor&#xD;
&#xD;
          -  Tumor &lt; 1.5 cm&#xD;
&#xD;
          -  &lt; 6 tumors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with porphyria&#xD;
&#xD;
          -  Known hypersensitivity to HexvixÂ® or porphyrins&#xD;
&#xD;
          -  Use of any anticoagulants&#xD;
&#xD;
          -  Macroscopic hematuria&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
&#xD;
          -  Expected poor compliance&#xD;
&#xD;
          -  Patients &lt; 18 years&#xD;
&#xD;
          -  Patients who do not read or understand Danish&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregers G Hermann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept Urology, Herlev/Gentofte hospital, Copenhagen, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urological department, Frederiksberg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Bispebjerg and Frederiksberg</investigator_affiliation>
    <investigator_full_name>Gregers Gautier Hermann</investigator_full_name>
    <investigator_title>consultant urologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

